## Neonatology

## Mark Turner, Wolfgang Goepel, Hector Rojas/Heike Rabe, Irja Lutsar, Evelyne Jacqz-Aigrain, Thorsten Olski, Harald Heinzl, Ralph Bax

## Meetings

Identify areas of shared concern
Potential topics included:

- Navigation of EMA website
- Pre-clinical models
- End-points
- Designs
- When to study neonates


## Meetings

Identify areas of shared concern
Potential topics included:

- Navigation of EMA website
- Pre-clinical models
- End-points
- Designs
- When to study neonates


## Not easy to agree a common topic to work on

## Subsequent events

- FDA set up a Neonatal Scientific Advisory Panel (as a result of increased emphasis on neonates after FDASIA)
- FDA is considering a stakeholders meeting to examine areas of shared concern
- Similar potential list to the list drawn up by the WG
- Pause to maximise value of efforts by working with FDA


## Next steps

- Develop more interest from the clinical community
- For example, meeting at European Society for Paediatric Research hosted by the Clinical Pharmacology Section (Karel Allegaert)


## Neonatal Medicines Research in Europe:

## opportunities and influences

Objectives of meeting:

- To brief participants about the global and

European context for research about medicines in neonates, with particular reference to industry studies

- To explore the opportunities for forming a European neonatal medicines research network
- To discuss concerns shared with regulators (EMA and FDA)


## Neonatal Medicines Research in Europe:

## opportunities and influences

Outcomes of meeting:

- Improved awareness of the opportunities for neonatal medicines research
- Action plan / recommendations for a European neonatal medicines research network
- Feedback to the groups in discussion with EMA / FDA

